Activation of PPARγ and δ by dietary punicic acid ameliorates intestinal inflammation in mice

British Journal of Nutrition

Volumn 106, Issue 6, 2011, Pages 878-886

  Bassaganya Riera, Josep ^a   DiGuardo, Margaret ^b   Climent, Montse ^a   Vives, Cristina ^a   Carbo, Adria ^a   Jouni, Zeina E ^c   Einerhand, Alexandra W C ^d   O'Shea, Marianne ^d   Hontecillas, Raquel ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^b Nutrition Therapeutics Inc   (United States)

^c Mead Johnson Nutritionals   (United States)

^d Lipid Nutrition BV   (United States)

Author keywords

Inflammatory bowel disease; PPAR; Punicic acid

Indexed keywords

DEXTRAN SULFATE; FATTY ACID; INTERLEUKIN 10; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PUNICIC ACID; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; LINOLENIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIETARY INTAKE; ENTERITIS; EPITHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IMMUNOREGULATION; IN VITRO STUDY; MACROPHAGE FUNCTION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; UPREGULATION; WILD TYPE; ANIMAL; ANIMAL FOOD; C57BL MOUSE; CYTOLOGY; GENE DELETION; GENETICS; INFLAMMATION; INTESTINE; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TRANSGENIC MOUSE;

MUS;

ANIMAL FEED; ANIMALS; ANTI-INFLAMMATORY AGENTS; GENE DELETION; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTESTINAL MUCOSA; INTESTINES; LINOLENIC ACIDS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PPAR DELTA; PPAR GAMMA; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 80555143144     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114511001188     Document Type: Article

References (55)

1. Strober W, Fuss IJ & Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20, 495-549. (Pubitemid 34293433)
2. Katayama K, Wada K, Nakajima A, et al. (2003) A novel PPARgamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 124, 1315-1324. (Pubitemid 36531806)
3. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127, 777-791. (Pubitemid 39208411)
4. Lytle C, Tod TJ, Vo KT, et al. (2005) The peroxisome proliferator- activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 11, 231-243. (Pubitemid 40439677)
5. Lewis JD, Lichtenstein GR, Deren JJ, et al. (2008) Rosiglitazone for active ulcerative colitis: A randomized placebocontrolled trial. Gastroenterology 134, 688-695. (Pubitemid 351312727)
6. Marcy TR, Britton ML & Blevins SM (2004) Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 38, 1419-1423. (Pubitemid 39100194)
7. Nesto RW, Bell D, Bonow RO, et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation 108, 2941-2948. (Pubitemid 37517824)
8. Hontecillas R, Wannemeulher MJ, Zimmerman DR, et al. (2002) Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. J Nutr 132, 2019-2027. (Pubitemid 34742894)
9. Bassaganya-Riera J & Hontecillas R (2006) CLA and n-3 PUFA differentially modulate clinical activity and colonic PPARresponsive gene expression in a pig model of experimental IBD. Clin Nutr 25, 454-465. (Pubitemid 43843028)
10. Hontecillas R, Diguardo M, Duran E, et al. (2008) Catalpic acid decreases abdominal fat deposition, improves glucose homeostasis and upregulates PPAR alpha expression in adipose tissue. Clin Nutr 27, 764-772.
11. Hontecillas R, O'Shea M, Einerhand A, et al. (2009) Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J Am Coll Nutr 28, 184-195.
12. Sassano GP, Sanderson J, Franx P, et al. (2009) Analysis of pomegranate seed oil for the presence of jacaric acid. J Food Sci Agric 6, 1046-1052.
13. Ahlers NHE, Dennison AC & O'Neill LA (1954) Spectroscopic examination of punicic acid. Nature 173, 1045-1046.
14. Kaufman M & Wiesman Z (2007) Pomegranate oil analysis with emphasis on MALDI-TOF/MS triacylglycerol fingerprinting. J Agric Food Chem 55, 10405-10413.
15. Bassaganya-Riera J, Hontecillas R & Beitz DC (2002) Colonic anti-inflammatory mechanisms of conjugated linoleic acid. Clin Nutr 21, 451-459. (Pubitemid 35452508)
16. O'Shea M, Bassaganya-Riera J & Mohede IC (2004) Immunomodulatory properties of conjugated linoleic acid. Am J Clin Nutr 79, Suppl. 6, 1199S-1206S.
17. McFarlin BK, Strohacker KA & Kueht ML (2009) Pomegranate seed oil consumption during a period of high-fat feeding reduces weight gain and reduces type 2 diabetes risk in CD-1 mice. Br J Nutr 102, 54-59.
18. Arao K, Wang YM, Inoue N, et al. (2004) Dietary effect of pomegranate seed oil rich in 9cis, 11trans, 13cis conjugated linolenic acid on lipid metabolism in obese, hyperlipidemic OLETF rats. Lipids Health Dis 3, 24.
19. Meerts IA, Verspeek-Rip CM, Buskens CA, et al. (2009) Toxicological evaluation of pomegranate seed oil. Food Chem Toxicol 47, 1085-1092.
20. Boussetta T, Raad H, Letteron P, et al. (2009) Punicic acid a conjugated linolenic acid inhibits TNFalpha-induced neutrophil hyperactivation and protects from experimental colon inflammation in rats. PLoS One 4, e6458.
21. Kohno H, Suzuki R, Yasui Y, et al. (2004) Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. Cancer Sci 95, 481-486. (Pubitemid 38832696)
22. Akiyama TE, Sakai S, Lambert G, et al. (2002) Conditional disruption of the peroxisome proliferator-Activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22, 2607-2619. (Pubitemid 34262983)
23. Wagner KU, McAllister K, Ward T, et al. (2001) Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 10, 545-553. (Pubitemid 34043179)
24. Cui Y, Miyoshi K, Claudio E, et al. (2002) Loss of the peroxisome proliferation-Activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 277, 17830-17835. (Pubitemid 34967591)
25. Barak Y, Liao D, He W, et al. (2002) Effects of peroxisome proliferator-Activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 99, 303-308. (Pubitemid 34060358)
26. Adachi M, Kurotani R, Morimura K, et al. (2006) Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55, 1104-1113. (Pubitemid 44085676)
27. Mohapatra SK, Guri AJ, Climent M, et al. (2010) Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental IBD. PLOS One 5, e10215.
28. Wohlfert EA, Nichols FC, Nevius E, et al. (2007) Peroxisome proliferator-Activated receptor gamma (PPARgamma) and immunoregulation: Enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 178, 4129-4135. (Pubitemid 46492362)
29. Shah Y, Morimura K & Gonzalez F (2006) Expression of peroxisome proliferator-Activated receptor-{gamma} in macrophage suppresses experimentally-induced colitis. Am J Physiol Gastrointest Liver Physiol 292, G657-G666.
30. Hontecillas R, Horne WT, Guri AJ, et al. (2010) Immunoregulatory mechanisms of macrophage PPAR gamma in mice with experimental inflammatory bowel disease. Mucosal Immunol, 4, 304-313.
31. Reeves PG, Nielsen FH & Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: Final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123, 1939-1951. (Pubitemid 23342492)
32. Saubermann LJ, Beck P, De Jong YP, et al. (2000) Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 119, 119-128. (Pubitemid 30452585)
33. Bassaganya-Riera J, Ferrer G, Casagran O, et al. (2009) F4/ 80hiCCR2hi macrophage infiltration into the intra-Abdominal fat worsens the severity of experimental IBD in obese mice with DSS colitis. e-SPEN J, 4, 90-97.
34. Hontecillas R & Bassaganya-Riera J (2007) Peroxisome proliferator- activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 178, 2940-2949. (Pubitemid 46333173)
35. Bassaganya-Riera J, Pogranichniy RM, Jobgen SC, et al. (2003) Conjugated linoleic acid ameliorates viral infectivity in a pig model of virally induced immunosuppression. J Nutr 133, 3204-3214. (Pubitemid 37222243)
36. Bassaganya-Riera J, Guri AJ, Noble AM, et al. (2007) Arachidonic acid and docosahexaenoic acid-enriched formulas modulate antigen-specific T cell responses to influenza virus in neonatal piglets. Am J Clin Nutr 85, 824-836. (Pubitemid 46393516)
37. Cantorna MT, Munsick C, Bemiss C, et al. (2000) 1,25- Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 130, 2648-2652.
38. Geerling BJ, Badart-Smook A, Stockbrugger RW, et al. (1998) Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 67, 919-926. (Pubitemid 28196667)
39. Calder PC (1998) Dietary fatty acids and the immune system. Nutr Rev 56, (1 Pt 2), S70-S83. (Pubitemid 28069972)
40. Birt DF, Copenhaver J, Barnett T, et al. (1997) Dietary fat and energy modulation of biochemical events in tumor promotion. Adv Exp Med Biol 400B, 925-929.
41. Liu Y, Duysen E, Yaktine AL, et al. (2001) Dietary energy restriction inhibits ERK but not JNK or p38 activity in the epidermis of SENCAR mice. Carcinogenesis 22, 607-612. (Pubitemid 32288662)
42. Bassaganya-Riera J & Hontecillas R (2010) Dietary conjugated linoleic acidandn-3polyunsaturatedfatty acids ininflammatory bowel disease. Curr Opin Clin Nutr Metab Care 13, 569-573.
43. Jump DB & Clarke SD (1999) Regulation of gene expression by dietary fat. Annu Rev Nutr 19, 63-90. (Pubitemid 29380597)
44. Su CG, Wen X, Bailey ST, et al. (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104, 383-389. (Pubitemid 29534322)
45. Desreumaux P, Dubuquoy L, Nutten S, et al. (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-Activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193, 827-838. (Pubitemid 32524532)
46. Nakajima A, Wada K, Miki H, et al. (2001) Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia- reperfusion injury. Gastroenterology 120, 460-469. (Pubitemid 32147643)
47. Nakajima A, Wada K, Katayama K, et al. (2002) Gene expression profile after peroxisome proliferator activator receptor-gamma ligand administration in dextran sodium sulfate mice. J Gastroenterol 37, Suppl. 14, 62-66. (Pubitemid 35385929)
48. Michalik L, Desvergne B, Tan NS, et al. (2001) Impaired skin wound healing in peroxisome proliferator-Activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154, 799-814. (Pubitemid 34292961)
49. Ricote M, Li AC, Willson TM, et al. (1998) The peroxisome proliferator-Activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82. (Pubitemid 28079218)
50. Kelly D, Campbell JI, King TP, et al. (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5, 104-112. (Pubitemid 38081475)
51. Pascual G, Fong AL, Ogawa S, et al. (2005) A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437, 759-763. (Pubitemid 41486547)
52. Kang K, Reilly SM, Karabacak V, et al. (2008) Adipocytederived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 7, 485-495. (Pubitemid 351729204)
53. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116-1120. (Pubitemid 47014427)
54. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, et al. (2008) Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7, 496-507. (Pubitemid 351729205)
55. Welch JS, Ricote M, Akiyama TE, et al. (2003) PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A 100, 6712-6717. (Pubitemid 36666645)